Immune Response BioPharma, Inc. NeuroVax vs. Interferon B-1a Phase 2B Clinical Study Update
- Category: Proteins and Peptides
- Published on Wednesday, 14 March 2012 23:56
- Hits: 495
mmune Response BioPharma, Inc. NeuroVax vs. Interferon B-1a Phase 2B Clinical Study Update
New York, NY, USA I March 13, 2012 I Immune Response BioPharma, Inc. estimates we should be begin recruiting for the new Phase 2B NeuroVax study by year end. Our IND should be filed within 60-90 days and the official trial should be uploaded to clinicaltrials.gov once finalized. The trial will test efficacy, safety and tolerance vs a comparable drug Interferon B-1a for 12 months and a minimum of 200 patients total who get the NeuroVax drug. The lead clinical investigator from OHSU Oregon Health & Science University is Dr. Dennis Bourdette an expert in Neurology and Multiple Sclerosis has vast experience and has led the previous NeuroVax trials.
"We are pleased with our progress to date our new patent portfolio includes the IP coverage until 2027 in the U.S.A. and we are expecting an allowance from Canada shortly. Funding has been our big issue with NeuroVax and we have had some very fruitful discussions with several potential partners, some big pharma types and some small biotechs. We are shooting for 2017 approval and 10% market-share for NeuroVax and with the right corporate partner we should get there with their help and expertise" Mr. Buswell CEO IRBP.
"NeuroVax is a game changer with safe once a month dosing compared to the only current once a month MS approved drug Tysabri as it does not have the PML or brain infection worries. I would expect this trial to be oversubscribed once up and running and recruiting. Many MS patients have contacted us wanting an update to when we will begin enrolling patients" IRBP CEO Mr. Buswell.
"Hopefully we enter into a corporate partnership sooner rather than later. Any pharma with current MS drugs going off patent or any who don't have a potential blockbuster MS drug like NeuroVax would be foolish to not partner with IRBP. NeuroVax will create winners and losers in this space. The winners will be the corporate partner and of course patients" IRBP CEO Mr. Buswell.
"We are cautiously optimistic we complete a deal in the near future. I am only happy to help bring this wonderful MS treatment to patients who need a safe alternative therapy and help the inventor Dr. Arthur Vandenbark and the OHSU team get their drug eventually FDA approved to help those patients suffering from this debilitating disease" IRBP CEO Mr. Buswell.
Immune Response BioPharma, Inc. maybe found on the world wide web at www.immuneresponsebiopharma.com
SOURCE: Immune Response BioPharma